Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down

Altimmune Inc. announced that Stephen Durso will take over as Chief Executive Officer, succeeding Vipin Garg, effective immediately. The leadership change marks a significant transition for the company, which focuses on developing therapies for liver disease and immune modulation. Garg has served as CEO since 2018 and oversaw several key developments during his tenure.

The announcement comes alongside updates from other organizations in the biotech sector. Circle Therapeutics reported advancements in its clinical trials, NRG Pharmaceuticals disclosed new strategic partnerships, Ovid Therapeutics shared progress on its neurological treatment pipeline, and Tacalyx provided details on its immunotherapy research initiatives. These updates highlight ongoing activity across the industry as companies continue to pursue innovative solutions in healthcare.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Rohin Iyer Highlights Rising Approval Rates and Cold Chain Challenges in Cell and Gene Therapy at Advanced Therapies Week 2025 Food Companies Collaborate with MAHA Movement Leaders to Challenge Ultra-Processed Diets WCG Launches ClinSphere eReview Manager to Streamline IRB Review Process in Clinical Research IFNγ Signaling in Tumor-Associated Myeloid Cells Linked to Resistance Against Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

Author

GOAI